NASDAQ:MURA Mural Oncology 5/14/2025 Earnings Report $2.48 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.46 -0.02 (-0.60%) As of 06/27/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Mural Oncology EPS ResultsActual EPS-$1.93Consensus EPS -$2.12Beat/MissBeat by +$0.19One Year Ago EPSN/AMural Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMural Oncology Announcement DetailsQuarterDate5/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsMural Oncology's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Mural Oncology Earnings HeadlinesForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 16, 2025 | markets.businessinsider.comBlackRock discloses 1.64% stake in Mural OncologyJune 13, 2025 | investing.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.June 28 at 2:00 AM | Brownstone Research (Ad)Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 13, 2025 | markets.businessinsider.comBlackRock discloses 1.39% stake in Mural OncologyJune 12, 2025 | investing.comBlackRock Reveals 1.58% Holding in Mural OncologyJune 5, 2025 | msn.comSee More Mural Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mural Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mural Oncology and other key companies, straight to your email. Email Address About Mural OncologyMural Oncology (NASDAQ:MURA), a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.View Mural Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
